Androgen Receptor Roles in Benign and Malignant Prostate Disease
Androgen deprivation therapy (ADT), which aims to reduce androgen–androgen receptor (AR) signaling, is the normal method of prostate cancer treatment. Despite its early success in suppressing prostate tumor growth, the therapy eventually fails, leading to recurrent hormone-refractory tumor growth. R...
Format: | Article |
---|---|
Language: | English |
Published: |
China Anti-Cancer Association
2011-06-01
|
Series: | Cancer Biology & Medicine |
Subjects: | |
Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/49 |
Similar Items
-
Androgen receptor and prostate cancer
by: Karen E. Livermore, et al.
Published: (2016-06-01) -
Factors that influence the androgen receptor cistrome in benign and malignant prostate cells
by: Ben T. Copeland, et al.
Published: (2019-12-01) -
Cell‐by‐cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression
by: Seta Derderian, et al.
Published: (2023-07-01) -
Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review
by: Tae Jin Kim, et al.
Published: (2021-03-01) -
Immunohistochemical expression of androgen receptors in prostate carcinoma and benign prostatic hyperplasia
by: Trivunić-Dajko Sandra, et al.
Published: (2020-01-01)